Swedish Orphan Biovitrum AB (SOBIV)

142.00
-1.05(-0.73%)
  • Volume:
    495,282
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    141.90 - 143.65

SOBIV Overview

Prev. Close
143.05
Day's Range
141.9 - 143.65
Revenue
15.26B
Open
143
52 wk Range
135.4 - 240.8
EPS
10.88
Volume
495,282
Market Cap
41.88B
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
915,965
P/E Ratio
13.14
Beta
0.91
1-Year Change
-15.88%
Shares Outstanding
294,896,839
Next Earnings Date
May 04, 2021
What is your sentiment on Swedish Orphan Biovitrum AB?
or
Market is currently closed. Voting is open during market hours.

Swedish Orphan Biovitrum AB News

Swedish Orphan Biovitrum AB Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong BuyStrong Sell
SummaryStrong SellStrong SellStrong SellNeutralStrong Sell

Swedish Orphan Biovitrum AB Company Profile

Swedish Orphan Biovitrum AB Company Profile

Employees
1471
Market
Sweden

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.